Logo
x

Search

Subscribe Now
Puma Biotechnology Commences the P-II (ALISCA-Breast1) Study of Alisertib in HR-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Commences the P-II (ALISCA-Breast1) Study of Alisertib in HR-Positive, HER2-Negative Metastatic Breast Cancer

  • November 22, 2024
Bayer Reports the US FDA’s sBLA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

Bayer Reports the US FDA’s sBLA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

  • November 22, 2024
Fresenius Kabi Reports the Reguatory Submission to the US FDA for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram

Fresenius Kabi Reports the Reguatory Submission to the US FDA for the Aurora Xi Plasmapheresis System Software Version 2.0 with Ne...

  • November 22, 2024
GSK’s Arexvy Vaccine Receives the MHLW’s Approval for its Expanded Age Indication to Prevent RSV Disease

GSK’s Arexvy Vaccine Receives the MHLW’s Approval for its Expanded Age Indication to Prevent RSV Disease

  • November 22, 2024
Xenetic Biosciences Reports Preclinical Data of Potential Co-Administration of DNase I with CAR T Cells for Melanoma Lung Metastasis

Xenetic Biosciences Reports Preclinical Data of Potential Co-Administration of DNase I with CAR T Cells for Melanoma Lung Metastas...

  • November 22, 2024
Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B

Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B

  • November 22, 2024
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.